已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia

维甲酸 维甲酸 急性早幼粒细胞白血病 生物 维甲酸 癌症研究 分化疗法 白血病 转录因子 细胞生物学 受体 核受体 髓样 细胞分化 生物化学 免疫学 基因
作者
Metis Hasipek,Yihong Guan,Dale Grabowski,Xiaorong Gu,Jaroslaw P. Maciejewski,Yogenthiran Saunthararajah,Hetty E. Carraway,Babal K. Jha
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (Supplement 1): 786-786
标识
DOI:10.1182/blood-2021-151394
摘要

Abstract Introduction: Retinoic acid (RA), an active metabolite of vitamin A, activates the retinoic acid receptors (RARs), ligand-controlled transcription factors that regulate expression of target genes affecting homeostasis and cellular differentiation. The success of RA in the form of all-trans retinoic acid (ATRA) to treat acute promyelocytic leukemia (APL) has stimulated considerable interest in the development of small molecules to modulate RARs in AML cells. Besides RARs, RA can also activate the pro-survival peroxisome proliferator-activated receptor β/δ (PPARβ/δ), a member of the nuclear hormone receptor superfamily of transcription factors that regulate several metabolic pathways in a tissue-selective manner. In the aqueous intracellular milieu, RA is transported by two alternative carriers, cellular retinoid-binding protein CRABP2, or fatty-acid-binding protein 5 (FABP5). These carriers preferentially deliver RA to RARs or PPARβ/δ respectively. In cells, expressing high CRABP2 and low FABP5, RA is delivered to and activates RARs, whereas in the presence of the reverse ratio, RA is delivered to and activates PPARβ/δ. Here we demonstrate that these two different modes of RA delivery leads to opposite cellular outcomes: CRABP2-mediated RA delivery to RAR prompts differentiation and growth arrest, while in cells containing high levels of FABP5, RA delivery to PPARβ/δ promotes survival and exponential proliferation. Inhibiting FABP5 carrier-function could be a useful method, therefore, to extend RA therapeutic activity to non-APL acute myeloid leukemia (AML). Methods: Genetic as well as pharmacologic in vitro and in vivo models of AML were used to validate FABP5 as a target for therapy to, increase RA stimulation of RARs instead of PPARβ/δ. Knockdown and overexpression of key regulators of these pathways were rationally used to understand pro-survival effects and proliferative mechanism of malignant myeloid cells. The efficacy of small molecule pharmacophore targeting FABP5 was evaluated in vitro in cell free and cell culture model as well as in vivo small animal model systems as a proof of therapeutic concept. Results: In public databases of AML gene expression, the majority of non-APL AMLs demonstrated upregulation of FABP5 and downregulation of CRABP2, potentially explaining limited benefit of RA to treat non-APL AMLs. On the other hand, ATRA sensitive APL samples demonstrated low FABP5, as expected from the established efficacy of RA to treat APLs. The greatest elevations of pro-survival FABP5 was in AMLs with mutated-NPM1. Consistent with the elevated FABP5 in these cells, we confirmed that RA activates pro-survival PPARβ/δ rather than pro-differentiation RAR in NPM1-mutated AML cells. We thus evaluated if inhibiting FABP5 could produce ATRA sensitization in NPM1 mutant AML cells. Genetic ablation of FABP5 using shRNA sensitized AML cells to ATRA treatment, while this effect was not seen in AML cells transfected with non-targeting scrambled shRNA. Cells stably expressing shRNA targeting FABP5 has significant growth perturbation in vivo in murine AML model. To target FABP5 using a small molecule approach, we used in silico drug-design to develop a novel small molecule FABP5 inhibitor (iFABP5): the inhibitor bound to recombinant FABP5 (Kd= 2x10 -7) with a 56-fold higher affinity than ATRA (Kd=11x10 -6 Mole), demonstrated in a cell free fluorescence reporter binding assay using 8-Anilino-1-naphthalenesulfonic acid (ANS). We then treated RA-resistant AML cells with iFABP5 alone and in combination with RA: neither iFABP5 nor RA alone had anti-proliferative activity as expected, but combination iFABP5 + RA downregulated PPARβ/δ target genes and upregulated RAR target genes, terminating AML cells growth. Conclusion: The lack of effective ATRA response in AML might be, in part, due to high expression of FABP5 and delivery of RA to pro-survival PPARβ/δ. A small molecule inhibitor of FABP5 could redirect RA to pro-terminal-differentiation RARs, and could be an approach to extending the remarkable activity of RA in APL to other AMLs. Reprogramming of the RA delivery to RAR pathway with the addition of a small molecular inhibitor of FABP5 could potentially restore therapeutic effects of ATRA in FABP5 over expressing cases of AML subtypes. Disclosures Maciejewski: Regeneron: Consultancy; Novartis: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; Alexion: Consultancy. Saunthararajah: EpiDestiny: Consultancy, Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Carraway: Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Other: Independent review committee; Celgene, a Bristol Myers Squibb company: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Stemline: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Other: Independent review committee; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astex: Other: Independent review committee.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
morningxiaoyi完成签到 ,获得积分10
2秒前
Sienna完成签到,获得积分10
4秒前
有魅力的煎蛋完成签到,获得积分10
6秒前
谢峥嵘发布了新的文献求助10
9秒前
郎治宇完成签到,获得积分10
14秒前
张包子完成签到 ,获得积分10
15秒前
17秒前
啦啦啦发布了新的文献求助10
17秒前
19秒前
星辰大海应助爱吃酥饼采纳,获得10
20秒前
迷途发布了新的文献求助10
22秒前
美好黑猫完成签到 ,获得积分10
24秒前
25秒前
拔萝卜鸭完成签到,获得积分10
25秒前
lx33101128发布了新的文献求助10
26秒前
完美世界应助nav采纳,获得10
26秒前
科研通AI2S应助啦啦啦采纳,获得10
26秒前
七月发布了新的文献求助20
28秒前
思源应助煞笔导去死啊采纳,获得10
28秒前
Orange应助迷途采纳,获得10
29秒前
32秒前
天天快乐应助Aria_chao采纳,获得10
37秒前
闾丘笑卉发布了新的文献求助10
37秒前
37秒前
支问凝发布了新的文献求助20
38秒前
机灵的青雪完成签到,获得积分10
38秒前
科研通AI2S应助科研通管家采纳,获得10
38秒前
爆米花应助科研通管家采纳,获得10
39秒前
科研通AI2S应助科研通管家采纳,获得10
39秒前
科研通AI2S应助科研通管家采纳,获得10
39秒前
科研通AI2S应助科研通管家采纳,获得10
39秒前
llll完成签到 ,获得积分10
39秒前
清脆的飞丹完成签到,获得积分10
40秒前
40秒前
41秒前
绿油枸枸发布了新的文献求助10
42秒前
Hosea发布了新的文献求助30
43秒前
CipherSage应助符水采纳,获得10
44秒前
45秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146415
求助须知:如何正确求助?哪些是违规求助? 2797811
关于积分的说明 7825766
捐赠科研通 2454165
什么是DOI,文献DOI怎么找? 1306196
科研通“疑难数据库(出版商)”最低求助积分说明 627666
版权声明 601503